Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Indiana University School of Medicine 2008
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
• Research
• 

  Selected Grants

  • TOP 1705 awarded by Bristol-Myers Squibb Company 2018 - 2023
  • SPI-POZ-202 awarded by Spectrum Pharmaceuticals, Inc 2017 - 2022
  • M15-534 awarded by AbbVie Inc. 2017 - 2022
  • Bayer 16044 awarded by Bayer HealthCare AG 2017 - 2021
  • A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance awarded by Adaptimmune Limited 2016 - 2021
  • Adaptimmune MAGE A-4 awarded by Adaptimmune Limited 2018 - 2020
  • Genentech GO29537 awarded by F. Hoffmann-La Roche Ltd 2015 - 2020
  • A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors awarded by Bristol-Myers Squibb Company 2015 - 2020
  • An Open label phase II study evaluatint Traztuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in patients who have advanced cancer awarded by Genentech, Inc. 2016 - 2020
  • mRNA-4157-P101 awarded by Moderna Therapeutics, Inc. 2017 - 2019
  • Adaptimmune MAGE awarded by Adaptimmune Limited 2018 - 2019
  • First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors awarded by MedPacto, Inc 2014 - 2019
  • A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or G awarded by Pfizer, Inc. 2013 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer awarded by Lung Cancer Initiative of North Carolina 2015 - 2018
  • Lilly H9H-MC-JBEF awarded by Eli Lilly and Company 2016 - 2018
  • Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2016 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Pabla, S, Conroy, JM, Nesline, MK, Glenn, ST, Papanicolau-Sengos, A, Burgher, B, Hagen, J, Giamo, V, Andreas, J, Lenzo, FL, Yirong, W, Dy, GK, Yau, E, Early, A, Chen, H, Bshara, W, Madden, KG, Shirai, K, Dragnev, K, Tafe, LJ, Marin, D, Zhu, J, Clarke, J, Labriola, M, McCall, S, Zhang, T, Zibelman, M, Ghatalia, P, Araujo-Fernandez, I, Singavi, A, George, B, MacKinnon, AC, Thompson, J, Singh, R, Jacob, R, Dressler, L, Steciuk, M, Binns, O, Kasuganti, D, Shah, N, Ernstoff, M, Odunsi, K, Kurzrock, R, Gardner, M, Galluzzi, L, and Morrison, C. "Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients." Journal for Immunotherapy of Cancer 7, no. 1 (February 2019): 27-null.  Full Text
    • Shariff, AI, Syed, S, Shelby, RA, Force, J, Clarke, JM, D'Alessio, D, and Corsino, L. "Novel cancer therapies and their association with diabetes." Journal of Molecular Endocrinology 62, no. 2 (February 2019): R187-R199. (Review)  Full Text
    • Conroy, JM, Pabla, S, Nesline, MK, Glenn, ST, Papanicolau-Sengos, A, Burgher, B, Andreas, J, Giamo, V, Wang, Y, Lenzo, FL, Bshara, W, Khalil, M, Dy, GK, Madden, KG, Shirai, K, Dragnev, K, Tafe, LJ, Zhu, J, Labriola, M, Marin, D, McCall, SJ, Clarke, J, George, DJ, Zhang, T, Zibelman, M, Ghatalia, P, Araujo-Fernandez, I, de la Cruz-Merino, L, Singavi, A, George, B, MacKinnon, AC, Thompson, J, Singh, R, Jacob, R, Kasuganti, D, Shah, N, Day, R, Galluzzi, L, Gardner, M, and Morrison, C. "Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors." Journal for Immunotherapy of Cancer 7, no. 1 (January 24, 2019): 18-null.  Full Text
    • Velikova, G, Williams, LJ, Willis, S, Dixon, JM, Loncaster, J, Hatton, M, Clarke, J, Kunkler, IH, Russell, NS, Alhasso, A, Adamson, D, Algurafi, H, Allerton, R, Anandadas, C, Bahl, A, Barraclough, L, Barrett-Lee, P, Barthakur, U, Bedi, C, Beresford, M, Bishop, J, Blackman, G, Bliss, P, Bloomfield, D, Blunt, M, Branson, T, Brazil, L, Brunt, A, Chakrabarti, A, Chittalie, A, Churn, M, Cleator, S, Crellin, P, Danwata, F, De-Silva-Minor, S, Dhadda, A, Eicholz, A, Fernando, I, Forrest, J, Fraser, J, Goodman, A, Grieve, R, Griffin, M, Hadaki, M, Hall, A, Hicks, J, Hignett, S, Hogg, M, Jyothirmayi, R, Khan, M, Konstantinos, G, Kumar, S, Lawton, P, Lee, D, Lewinski, C, Lim, C, Locke, I, Lumsden, G, Lupton, S, Magee, B, Marshall, J, Masinghe, S, McGregor, C, McLennan, M, Memtsa, P, Milanovic, D, Misra, V, Mithal, N, Mukesh, MB, Neal, A, Needleman, S, Persic, M, Quigley, M, Raj, S, Riddle, P, Ritchie, D, Roberts, F, Robson, P, Roe, H, Rolles, M, Shah, N, Sharma, R, Sherwin, E, Simmonds, P, Skailles, G, Skaria, S, Soe, W, Sripadam, R, Stevens, A, Stockdale, A, Storey, N, Syndikus, I, Thorp, N, Upadhyay, S, and Varughese, M. "Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial." The Lancet Oncology 19, no. 11 (November 1, 2018): 1516-1529.  Full Text
    • Marano, AL, Clarke, JM, Morse, MA, Shah, A, Barrow, W, Selim, MA, Hall, RP, and Cardones, AR. "Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy." The British Journal of Dermatology (September 23, 2018).  Full Text
    • DeMaio, A, Clarke, JM, Dash, R, Sebastian, S, Wahidi, MM, Shofer, SL, Cheng, GZ, Li, X, Wang, X, and Mahmood, K. "Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma." Journal of Bronchology & Interventional Pulmonology (July 25, 2018).  Full Text
    • Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.  Full Text
    • Yi, JS, Ready, N, Healy, P, Dumbauld, C, Osborne, R, Berry, M, Shoemaker, D, Clarke, J, Crawford, J, Tong, B, Harpole, D, D'Amico, TA, McSherry, F, Dunphy, F, McCall, SJ, Christensen, JD, Wang, X, and Weinhold, KJ. "Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474-7482.  Full Text
    • Bedoya, A, Glisinski, K, Clarke, J, Lind, RN, Buckley, CE, and Shofer, S. "Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases." The American Journal of Case Reports 18 (July 31, 2017): 842-846.  Full Text
    • Clarke, JM, Wang, X, and Ready, NE. "Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?." Translational Lung Cancer Research 4, no. 6 (December 2015): 804-808.  Full Text
    • Hatch, AJ, Clarke, JM, Nixon, AB, and Hurwitz, HI. "Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress." Cancer journal (Sudbury, Mass.) 21, no. 4 (July 2015): 322-326. (Review)  Full Text
    • Lyman, GH, Bohlke, K, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Somerfield, MR, Falanga, A, and American Society of Clinical Oncology, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 6 (February 2015): 654-656.  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective." Cancer treatment reviews 40, no. 9 (October 2014): 1065-1072. (Review)  Full Text
    • Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective." Cancer Treatment Reviews 40, no. 9 (2014): 1065-1072.  Full Text
    • Clarke, JM, and Hurwitz, HI. "Understanding and targeting resistance to anti-angiogenic therapies." J Gastrointest Oncol 4, no. 3 (September 2013): 253-263.  Full Text  Link to Item
    • Clarke, JM, and Hurwitz, HI. "Targeted inhibition of VEGF receptor 2: an update on ramucirumab." Expert Opinion on Biological Therapy 13, no. 8 (August 2013): 1187-1196. (Review)  Full Text
    • Lyman, GH, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Prestrud, AA, Falanga, A, and American Society of Clinical Oncology Clinical Practice, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 17 (June 2013): 2189-2204. (Review)  Full Text
    • Clarke, JM, and Armstrong, AJ. "Novel therapies for the treatment of advanced prostate cancer." Curr Treat Options Oncol 14, no. 1 (March 2013): 109-126. (Review)  Full Text  Link to Item
    • Clarke, JM, and Hurwitz, HI. "Ziv-aflibercept: binding to more than VEGF-A--does more matter?." Nature Reviews. Clinical Oncology 10, no. 1 (January 2013): 10-11.  Full Text
    • Mis, L, and Clarke, JM. "Ipilimumab-induced pneumonitis: A case report." Journal of Pharmacy Technology 29, no. 2 (January 1, 2013): 94-98.  Full Text
    • Clarke, JM, Morse, MA, Lyerly, HK, Clay, T, and Osada, T. "Adenovirus vaccine immunotherapy targeting WT1-expressing tumors." Expert Opin Biol Ther 10, no. 6 (June 2010): 875-883. (Review)  Full Text  Link to Item
    • Clarke, JM, and Helft, P. "Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: A case report and review of the literature." Journal of Medical Case Reports 4 (2010).  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148))." Journal of Surgical Oncology 100, no. 5 (October 1, 2009): 434-null.  Full Text
    • Struck, A, Howard, T, Chiorean, EG, Clarke, JM, Riffenburgh, R, and Cardenes, HR. "Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival." Journal of Surgical Oncology 100, no. 2 (August 2009): 144-148.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.